Skip to main content
BMJ Open Diabetes Research & Care logoLink to BMJ Open Diabetes Research & Care
. 2017 Sep 7;5(1):e000391corr1. doi: 10.1136/bmjdrc-2017-000391corr1

Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

PMCID: PMC5595186  PMID: 28948029

Kitada M, Shin-ichi T, Konishi K et al. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care 2017;5:e000391. doi:10.1136/bmjdrc-2017-000391.

The funding statement has been amended to: This work was financially supported by a grant from the Kidney Foundation, Japan and SANWA KAGAKU KENKYUSHO CO, LTD to DK.


Articles from BMJ Open Diabetes Research & Care are provided here courtesy of BMJ Publishing Group

RESOURCES